sofosbuvir has been researched along with Hepatic Encephalopathy in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y | 1 |
| El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A | 1 |
| Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M | 1 |
| Basha, MAA; Bassiony, MA; Hanafy, AS | 1 |
| Chen, YS; Kao, JH; Liu, CH; Wang, SS | 1 |
1 trial(s) available for sofosbuvir and Hepatic Encephalopathy
| Article | Year |
|---|---|
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
4 other study(ies) available for sofosbuvir and Hepatic Encephalopathy
| Article | Year |
|---|---|
Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
Topics: Balloon Occlusion; Carbamates; Female; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Middle Aged; Sofosbuvir; Treatment Outcome | 2020 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine | 2019 |
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir.
Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Fluorenes; Heart Failure; Heart Transplantation; Hepatic Encephalopathy; Hepatitis C; Humans; Liver Function Tests; Male; Middle Aged; Myocardial Infarction; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |